ClearPoint Neuro, Inc.
Close on Oct 19, 2026
- Market cap
- $276.63M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 3, 2026 | After market close | $10.90M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | $12.10M | $-0.32 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 17, 2026 | After market close | $10.40M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $8.90M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | $9.20M | $-0.21 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | $8.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | After market close | $7.80M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $8.10M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 3, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue | 2026 | $48.00M to $52.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements ClearPoint Neuro filed with the SEC
ClearPoint Neuro Reports Second Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT August 2026 1 © 2026 CLEARPOINT NEURO
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports First Quarter 2026 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT May 2026 1 © 2026 CLEARPOINT NEURO
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT March 2026 1 © 2026 CLEARPOINT NEURO
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
Results of operations · EX-99.1 to Form 8-K
ClearPoint Neuro Completes Acquisition of IRRAS
Material agreement · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
ClearPoint Neuro Reports Third Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT November 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Announces Agreement to Acquire IRRAS
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
ClearPoint Neuro Reports Second Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT August 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports First Quarter 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2025 CLEARPOINT NEURO WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT May 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing
Material agreement · Other events · EX-99.1 to Form 8-K
ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT February 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports Third Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2 0 2 4 C L E A R P O I N T N E U R O 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Announces Early Repayment of $10 Million Note
Regulation FD disclosure · EX-99.1 to Form 8-K
ClearPoint Neuro Reports Second Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2 0 24 C LE A R P OI N T NE UR O 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports First Quarter 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2 0 2 4 C L E A R P O I N T N E U R O 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2 0 2 4 C L E A R P O I N T N E U R O 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2 0 2 4 C L E A R P O I N T N E U R O 3 Our Company
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports Third Quarter 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2 0 2 3 C L E A R P O I N T N E U R O 10 VISUALASE *In approved clinical trials and preclinical studies.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports Second Quarter 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports First Quarter 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results
Results of operations · EX-99.1 to Form 8-K
ClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2 0 2 3 C L E A R P O I N T N E U R O 6 Leverage live MR Imaging to Decide, Guide, Treat and Confirm with sub-millimetric accuracy.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ClearPoint Neuro Reports Third Quarter 2022 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
© 2 0 2 2 C L E A R P O I N T N E U R O 6 Leverage live MR Imaging to Decide, Guide, Treat and Confirm with sub-millimetric accuracy.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K